Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CombiMatrix raises $8mm in FOPO

Executive Summary

Molecular diagnostics company CombiMatrix Corp. netted $7.5mm in a firm commitment follow-on public offering of 8,000 units of Series F convertible preferred stock and warrants at $1,000 per unit. Each unit consists of one Series F convertible preferred share convertible into 258.4 common shares (2,067,183 common shares if converted) at $3.87 per share, and 258.4 warrants to purchase one common share at $5.17 strike price (also convertible into 2,067,183 common shares). The proceeds will be used to repurchase and retire Series E convertible preferred stock.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
    • Nanotechnology, Chips, etc.
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Molecular Diagnostics & Genetic Testing
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
  • Services
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies